Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Jianmin Wang, Mohamed Ibrahim, Peykan Turkcuoglu, Elham Hatef, Afsheen Khwaja, Roomasa Channa, Diana V Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalOcular Immunology and Inflammation
Volume18
Issue number5
DOIs
StatePublished - Oct 1 2010

Fingerprint

Macular Edema
Cell Adhesion Molecules
Immunomodulation
Uveitis
Subcutaneous Injections
Therapeutics
Adrenal Cortex Hormones
Inflammation
Injections
efalizumab

Keywords

  • ICAM inhibitor
  • Macular edema
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Wang, J., Ibrahim, M., Turkcuoglu, P., Hatef, E., Khwaja, A., Channa, R., ... Nguyen, Q. D. (2010). Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocular Immunology and Inflammation, 18(5), 395-398. https://doi.org/10.3109/09273948.2010.483317

Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. / Wang, Jianmin; Ibrahim, Mohamed; Turkcuoglu, Peykan; Hatef, Elham; Khwaja, Afsheen; Channa, Roomasa; Do, Diana V; Nguyen, Quan Dong.

In: Ocular Immunology and Inflammation, Vol. 18, No. 5, 01.10.2010, p. 395-398.

Research output: Contribution to journalArticle

Wang, J, Ibrahim, M, Turkcuoglu, P, Hatef, E, Khwaja, A, Channa, R, Do, DV & Nguyen, QD 2010, 'Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema', Ocular Immunology and Inflammation, vol. 18, no. 5, pp. 395-398. https://doi.org/10.3109/09273948.2010.483317
Wang, Jianmin ; Ibrahim, Mohamed ; Turkcuoglu, Peykan ; Hatef, Elham ; Khwaja, Afsheen ; Channa, Roomasa ; Do, Diana V ; Nguyen, Quan Dong. / Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. In: Ocular Immunology and Inflammation. 2010 ; Vol. 18, No. 5. pp. 395-398.
@article{6d8f1b1608cc41089f3390002b2506c0,
title = "Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema",
abstract = "Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.",
keywords = "ICAM inhibitor, Macular edema, Uveitis",
author = "Jianmin Wang and Mohamed Ibrahim and Peykan Turkcuoglu and Elham Hatef and Afsheen Khwaja and Roomasa Channa and Do, {Diana V} and Nguyen, {Quan Dong}",
year = "2010",
month = "10",
day = "1",
doi = "10.3109/09273948.2010.483317",
language = "English (US)",
volume = "18",
pages = "395--398",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

AU - Wang, Jianmin

AU - Ibrahim, Mohamed

AU - Turkcuoglu, Peykan

AU - Hatef, Elham

AU - Khwaja, Afsheen

AU - Channa, Roomasa

AU - Do, Diana V

AU - Nguyen, Quan Dong

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

AB - Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

KW - ICAM inhibitor

KW - Macular edema

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=77956828128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956828128&partnerID=8YFLogxK

U2 - 10.3109/09273948.2010.483317

DO - 10.3109/09273948.2010.483317

M3 - Article

VL - 18

SP - 395

EP - 398

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 5

ER -